ALS is often called the "bankruptcy disease" due to the high cost of treatments and care. But the emotional costs can take a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Biogen (BIIB) stock received an upgrade from Wells Fargo to Overweight with a $250 price target from $200, driven by confidence in late-stage immunology and kidney pipeline programs as medium-term ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm. The ...

Biogen is acquiring Apellis Pharmaceuticals in a $5.6 billion deal that brings two FDA-approved products commercialized in four indications, all of which are expected to contribute to the revenue ...

Biogen CEO sees strategic value in Apellis' kidney disease drug Deal to be financed with cash and borrowings Apellis shares more than double, Biogen stock fell nearly 5% Deal to add to adjusted profit ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Biogen said Tuesday that it would buy ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Biogen is buying a Waltham ...

Please provide your email address to receive an email when new articles are posted on . The acquisition includes Syfovre for geographic atrophy and Empaveli for two rare kidney diseases and paroxysmal ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Biogen said Tuesday that ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...